Edwards Lifesciences Corporation (EW) Shares Bought by Toronto Dominion Bank

Toronto Dominion Bank boosted its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 24.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 71,106 shares of the medical research company’s stock after buying an additional 13,747 shares during the quarter. Toronto Dominion Bank’s holdings in Edwards Lifesciences Corporation were worth $8,406,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of EW. ETF Managers Group LLC acquired a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at approximately $112,000. Shine Investment Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at approximately $126,000. Cornerstone Advisors Inc. grew its position in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares during the last quarter. Alexandria Capital LLC grew its position in shares of Edwards Lifesciences Corporation by 1.7% in the second quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares during the last quarter. Finally, Captrust Financial Advisors acquired a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at approximately $149,000. Institutional investors own 82.06% of the company’s stock.



In related news, CEO Michael A. Mussallem sold 32,900 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $114.80, for a total transaction of $3,776,920.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Catherine M. Szyman sold 4,681 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $115.78, for a total value of $541,966.18. The disclosure for this sale can be found here. Over the last three months, insiders sold 195,861 shares of company stock worth $22,218,268. Insiders own 2.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Shares Bought by Toronto Dominion Bank” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another website, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this report can be read at https://www.dispatchtribunal.com/2017/10/27/edwards-lifesciences-corporation-ew-stake-raised-by-toronto-dominion-bank.html.

Shares of Edwards Lifesciences Corporation (EW) traded up 0.03% during midday trading on Friday, reaching $103.40. 481,140 shares of the company’s stock traded hands. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.45. The stock has a 50 day moving average of $111.02 and a 200-day moving average of $112.41. The stock has a market cap of $21.83 billion, a price-to-earnings ratio of 31.36 and a beta of 0.62.

Edwards Lifesciences Corporation (NYSE:EW) last released its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.86 by ($0.02). The business had revenue of $821.50 million during the quarter, compared to the consensus estimate of $833.85 million. Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business’s revenue was up 11.1% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.68 EPS. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.75 EPS for the current year.

Several research firms have recently commented on EW. Deutsche Bank AG lowered their price target on shares of Edwards Lifesciences Corporation from $122.00 to $115.00 and set a “hold” rating on the stock in a research report on Thursday. Morgan Stanley lowered their price target on shares of Edwards Lifesciences Corporation from $133.00 to $120.00 and set an “overweight” rating on the stock in a research report on Thursday. Barclays PLC decreased their target price on shares of Edwards Lifesciences Corporation from $120.00 to $118.00 and set an “equal weight” rating on the stock in a research report on Wednesday. SunTrust Banks, Inc. set a $124.00 price target on shares of Edwards Lifesciences Corporation and gave the stock a “buy” rating in a research note on Wednesday. Finally, Canaccord Genuity reissued a “buy” rating and issued a $135.00 target price (down previously from $155.00) on shares of Edwards Lifesciences Corporation in a research note on Wednesday. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $125.39.

Edwards Lifesciences Corporation Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply